AKT1 and neoplasm: SCRIPro specifically enriches SPIB, a driver regulator that mediates apoptosis through the PI3K-AKT pathway in diffuse B-cell lymphoma (Takagi et al. 2016), in tumor B-cells but not normal cells, while SCENIC+ fails to predict the SPIB activity in all the B-cells (Fig. 3d).